Common use of Generic Competition Clause in Contracts

Generic Competition. If, during a given calendar year, there is sale of a generic Sphingosomal Vincristine or sale of an approved equivalent to Sphingosomal Vincristine (collectively, “Approved Sphingosomal Vincristine Equivalents”) in any country in the Territory, then, for such country, the total amount of royalties payable to INEX for the Net Sales of Sphingosomal Vincristine in such country during such calendar year will be reduced to [*] of the royalties payable to INEX pursuant to Section 3.1.2 for such calendar year, in such country.

Generic Competition. (a) If, during a given calendar year, there is sale of a generic Sphingosomal Vincristine Topotecan or sale of an approved equivalent to Sphingosomal Vincristine Topotecan (collectively, “Approved Sphingosomal Vincristine Topotecan Equivalents”) in any country in the Territory, then, for such country, the total amount of royalties payable to INEX for the Net Sales of Sphingosomal Vincristine Topotecan in such country during such calendar year will be reduced to by [*] of the royalties payable to INEX pursuant to Section 3.1.2 3.3.2 for such calendar year, in such country.

Generic Competition. (a) If, during a given calendar year, there is sale of a generic Sphingosomal Vincristine Vinorelbine or sale of an approved equivalent to Sphingosomal Vincristine Vinorelbine (collectively, “Approved Sphingosomal Vincristine Vinorelbine Equivalents”) in any country in the Territory, then, for such country, the total amount of royalties payable to INEX for the Net Sales of Sphingosomal Vincristine Vinorelbine in such country during such calendar year will be reduced to [*] of the royalties payable to INEX pursuant to Section 3.1.2 3.2.2 for such calendar year, in such country.

Generic Competition. (a) If, during a given calendar year, there is sale of a generic Sphingosomal Vincristine Topotecan or sale of an approved equivalent to Sphingosomal Vincristine Topotecan (collectively, “Approved Sphingosomal Vincristine Topotecan Equivalents”) in any country in the Territory, then, for such country, the total amount of royalties payable to INEX for the Net Sales of Sphingosomal Vincristine Topotecan in such country during such calendar year will be reduced to by [***] percent ([***]%) of the royalties payable to INEX pursuant to Section 3.1.2 3.3.2 for such calendar year, in such country.

Generic Competition. (a) If, during a given calendar year, there is sale of a generic Sphingosomal Vincristine Topotecan or sale of an approved equivalent to Sphingosomal Vincristine Topotecan (collectively, “Approved Sphingosomal Vincristine Topotecan Equivalents”) in any country in the Territory, thenthem, for such country, the total amount of royalties payable to INEX for the Net Sales of Sphingosomal Vincristine Topotecan in such country during such calendar year will be reduced to [***] percent ([***]%) of the royalties payable to INEX pursuant to Section 3.1.2 3.3.2 for such calendar year, in such country.